Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2019-000954-67-IT
EUCTR2019-000954-67-ITActive, not recruitingPhase 1

A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease - AMICUS ATB200-07

AMICUS THERAPEUTICS, INC.0 sites120 target enrollmentStarted: June 17, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
120
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Subject must provide signed informed consent prior to any studyrelated procedures being performed.
  • •2. Subject must have completed Study ATB200-03.
  • •Note: Subjects who were forced to withdraw from Study ATB200-03 for a logistical reason not related to the efficacy or safety of ATB200/AT2221 (eg, hospitalization for a car accident or emergency surgery) and which resulted in several consecutive missed doses may be eligible to participate in this study upon approval by the Amicus medical monitor.
  • •3. Female subjects of childbearing potential and male subjects must agree to use medically accepted methods of contraception during the study and for 90 days after the last dose of study drug.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 100
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

  • •1. Subject plans to receive gene therapy or participate in another interventional study for Pompe disease.
  • •2. Subject has a medical condition or any other extenuating circumstance that may, in the opinion of the investigator or medical monitor, pose an undue safety risk to the subject or may compromise his/her ability to comply with or adversely impact protocol requirements. This includes clinical depression (as diagnosed by a psychiatrist or other mental health professional) with uncontrolled or poorly controlled symptoms.
  • •3. Subject, if female, is pregnant or breastfeeding.
  • •4. Subject, whether male or female, is planning to conceive a child during the study.

Investigators

Similar Trials

Recruiting
Phase 3
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe DiseaseGlycogen storage disease type II10028396Pompe disease
NL-OMON54552Amicus Therapeutics1
Active, not recruiting
Phase 3
ATB200/AT2221 Phase 3 Open-label Extension StudyPompe disease
JPRN-jRCT2011200003Wright Jacquelyn110
Active, not recruiting
Phase 1
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe disease
EUCTR2019-000954-67-GBAmicus Therapeutics, Inc.110
Active, not recruiting
Phase 1
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe diseaseAdult Subjects With Late Onset Pompe Disease (LOPD)MedDRA version: 24.0Level: LLTClassification code 10075702Term: Pompe's disease late onsetSystem Organ Class: 100000004850
EUCTR2019-000954-67-BEAmicus Therapeutics, Inc.110
Active, not recruiting
Phase 1
A study investigating the long-term safety and efficacy of intravenous (IV) ATB200 when Co-administrated with oral AT2221 in adult subjects with Pompe disease
EUCTR2019-000954-67-GRAmicus Therapeutics, Inc.110